Piper Sandler lowered the firm’s price target on Merit Medical (MMSI) to $106 from $113 and keeps an Overweight rating on the shares ahead of quarterly results. The firm notes management already pre-announced revenue, but it is calling for gross margin to surprise to the upside, and Piper can envision even conservative guidance from management leading to Street estimates nudging higher post-call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Amazon downgraded, Roblox upgraded: Wall Street’s top analyst calls
- Merit Medical initiated with a Buy at BTIG
- Merit Medical falls -8.1%
- Merit Medical Systems: Sustained Operating Momentum and Governance Clarity Support Continued Buy Rating
- Merit Medical Systems: Above-Consensus Growth and Stable Governance Support Reaffirmed Buy Rating